article thumbnail

STAT+: Oncologists more likely to provide low-value care after receiving pharma money, study finds

STAT

Oncologists were more likely to provide low-value cancer care after receiving money from pharmaceutical companies, and the findings raise questions about the extent to which industry influence may have led to patient harm, according to a new study. Continue to STAT+ to read the full story…

article thumbnail

The Issue with Reissue: PTE Edition

The FDA Law Blog

In the generic filers view, the regulatory review period should have started in January 2014 when the patent was reissued rather than in April 2004, when the IND was opened, because the reissued patent did not exist in April 2004. The plain text of 35 U.S.C. The Court thus explained that interpreting the patent in 35 U.S.C.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Novo Nordisk moves to strengthen obesity efforts

pharmaphorum

“Combining EraCal’s phenotypic screening platform with Novo Nordisk’s expertise within pharmaceutical peptides and metabolic diseases will contribute to the discovery of novel drug candidates for the treatment of obesity,” said Josua Jordi, CEO of EraCal. “We

FDA 123
article thumbnail

Increasing patient engagement with UK clinical trials

pharmaphorum

Pharmaceutical companies often struggle to actively involve patients in the design phase of clinical trials but doing so can have huge benefits for the sustainability and success of research. In 2014 Keith was fortunate to become a full-time salaried patient research ambassador at Liverpool Heart and Chest Hospital Trust.

article thumbnail

Cancer researchers unable to access clinical trial data for top-selling drugs, study finds

The Guardian - Pharmaceutical Industry

The authors of a study published in the journal JAMA Oncology on Friday said the lack of transparency should be concerning to Australia. Sign up to receive an email with the top stories from Guardian Australia every morning Continue reading.

article thumbnail

Abiogen acquires EffRx to fortify bone disease portfolio

Pharmaceutical Technology

The Italian pharmaceutical company Abiogen Pharma completed an acquisition of a 97.09% stake in the Swiss orphan conditions-focused EffRx Pharmaceuticals on May 29. Altamedics specialises in pharmaceutical distribution in hospital settings.

article thumbnail

Pfizer receives EU haemophilia B gene therapy approval

European Pharmaceutical Review

The company highlighted that the median annualised bleed rate (ABR) of zero bleeds was observed in the haemophilia B patients after up to four years of follow-up, Pfizer shared. The pharmaceutical company licensed the gene therapy DURVEQTIX from Spark ® Therapeutics in December 2014.